Retrieved Lymph Node Number Affects Prognosis in Gastric CA

This article originally appeared here.
Share this content:
Retrieved Lymph Node Number Affects Prognosis in Gastric CA
Retrieved Lymph Node Number Affects Prognosis in Gastric CA

FRIDAY, Sept. 30, 2016 (HealthDay News) -- In patients with pathological stage (pStage) II or III gastric cancer, the number of retrieved lymph nodes (RLNs) is an independent poor prognostic factor, according to a study published in the September issue of the Journal of Gastroenterology and Hepatology.

Wataru Okajima, from the Kyoto Prefectural University of Medicine in Japan, and colleagues retrospectively analyzed 1,289 consecutive gastric cancer patients who underwent gastrectomy between 1997 and 2011. The patients were divided into two groups with a cut-off RLN number of 16.

The researchers found that survival rates differed significantly for patients in pStage II (P < 0.0001) and III (P = 0.0009), but not for patients in pStage I (P = 0.0627) and IV (P = 0.1553). For 498 patients in pStage II and III, patients in the RLN <16 group had a significantly higher incidence in older age and positive lymph node ratio compared with patients in the RLN ≥16 group. An RLN number <16 was an independent poor prognostic factor (hazard ratio, 2.48; P < 0.0001) in univariate and multivariate analysis. In pStage II or III patients, a cut-off RLN of 16 could cause the stage migration effect. The prognostic effect could be eliminated by a cut-off RLN of 25 or more.

"The RLN number may potentially affect the prognosis and the stage migration in pStage II or III gastric cancer patients," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »